AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02534948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and acceptance group therapy
Description: The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
Study NCT04498923 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine, dexamethasone, epinephrine
Description: Bupivacaine 75 mg, dexamethasone 4 mg, epinephrine 0,18 mg
Study NCT03616184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Patients with sclerotic chronic graft-versus-host disease (GVHD) will receive oral ruxolitinib at a dose of 10 mg twice daily. Doses may not exceed 10 mg twice daily. Ruxolitinib will be continued for 6 months. Patients who continue to have stable disease, mixed responses or partial/complete responses at the end of 6 months may continue the drug for a total of 12 months.
Study NCT04413630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family workshop
Description: The family workshop with 5 courses, with 6 families in one course The intervention of one course; 2 hours per session, one time per week, for a total of 6 weeks
Study NCT03043001 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Memantine
Description: All the subjects will receive add-on memantine for 12 week
Study NCT01730898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study product containing lutein
Description: delivered in capsule form
Study NCT01730898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study product containing lutein
Description: delivered in capsule form
Study NCT02355002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
Study NCT02355002 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects.
Study NCT03533426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane catheter block
Description: Ultrasonographic guided placement of a catheter under the serratus anterior muscle in cases of open thoracotomies for chest malignancies in an attempt to reduce the emergence of postthoracotomy pain syndrome.
Study NCT03533426 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled analgesia
Description: The use of patient controlled analgesia through a pump aiming to reduce the development of postthoracotomy pain syndrome
Study NCT03371810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Description: Mobile therapeutic light (10.000 LUX, white light without UV light), daily (except Sunday) for 30 min in the morning or evening for 10 weeks in total at home provided by a bright light therapy device (Philips EnergyLight HF 3419). Monitoring and feedback will be realized with the m-Health system comprising of a smartphone equipped with the m-Health App, and an activity sensor equipped with a light sensor to monitor the light exposure of the participant.
Study NCT03371810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: During 10 weeks participants perform three days of aerobic activities proposed and in two of these days also do muscle-strengthening exercise. Specifically, a training day consists of: (i) a 5-min warm-up period, (ii) a 10-35 min of muscle-strength training on two of the three days, (iii) a 20-40 min of aerobic training, (iii), and a 5-min of flexibility/stretching cool-down. During the course of the 10 weeks, the duration and intensity of the exercises will increase gradually.~Instruction, monitoring, and feedback will be realised by the m-Health system including a smartphone equipped with the m-Health app and Secure Digital Memory cards to store the exercise videos as well as an activity sensor equipped with a mobile sensor for the acquisition of physical activity.
Study NCT05521425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helping Hands for CAPD bag exchange procedures
Description: Training served as Treatment As Usual (TAU) for all participants; The difference between two groups was whether Helping hands were provided to participants for CAPD bag exchange procedures at home.
Study NCT03077191 — intervention group
Intervention type: OTHER
Intervention: Quality of life measurement
Description: The quality of life of breast cancer patients treated with conservative surgery and adjuvant whole breast hypofractionated radiotherapy, without boost, will be evaluated.
Study NCT02483897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% ophthalmic drops
Description: 0.8 mls. drops provided to be used hourly p.r.n. for pain control
Study NCT02483897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline placebo drops
Description: 0.8 mls. drops provided to be used hourly p.r.n. for pain control
Study NCT04605848 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Infrared themrography
Description: measurement of temperature and microcirculation of the skin overlaying BAT depots in the region of FDG-uptake detected by 18F-FDG PET/CT before and after a cold test
Study NCT04609267 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PHQ-9 - Mirror format
Description: The intervention we will be using is a new delivery system of the PHQ-9 using an Amazon Alexa equipped Mirror device. This Mirror device is similar to a smart television with a mirror interface. The device records auditory responses to the PHQ-9. We will be comparing the responses from the Mirror device to those given on the clinically established paper format.
Study NCT01269996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Janumet, Lantus
Description: In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection.
Study NCT01269996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin, gliclazide, protaphane
Description: In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.~Treatment groups:~Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.~Group 2 - Janumet followed by Lantus insulin injection.
Study NCT01127282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)
Description: Vitamin (vitamin A 15 mg,C 500 mg, E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
Study NCT01127282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (digestive tablet)
Description: Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
Study NCT02732379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lavender Aromatherapy
Description: the two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
Study NCT02732379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rose Aromatherapy
Description: the two drops of rose essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
Study NCT02732379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ginger Aromatherapy
Description: the two drops of ginger essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
Study NCT02732379 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Aromatherapy
Description: the two drops of pure water will be dropped into the gauze and the patient will inhale it for 5 minutes
Study NCT00523159 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Endoxana, IMA901, Leukine
Description: a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
Study NCT00523159 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IMA901 and Leukine
Description: Intradermal injection of GM-CSF followed by intradermal injection of IMA901
Study NCT02621580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pan-Retinal Photocoagulation
Description: Diabetic retinopathy does not usually impair sight until the development of long-term complications, including proliferative retinopathy, a condition in which abnormal new blood vessels may rupture and bleed inside the eye. When this advanced stage of retinopathy occurs, pan-retinal photocoagulation is usually recommended.~During this procedure, a special laser is used to make tiny burns that seal the retina and stop vessels from growing and leaking. Hundreds of tiny spots of laser are placed in the retina to reduce the risk of vitreous haemorrhage and retinal detachment.
Study NCT02110901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRT-201
Study NCT02110901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03638206 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cell immunotherapy
Description: According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
Study NCT04667299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rabeprazole
Description: 20mg bid
Study NCT04667299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20mg bid
Study NCT04577274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: smoothie with regular formulas (SM)
Description: Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
Study NCT04577274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: smoothie with low carbohydrate formulas (SMLS)
Description: Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
Study NCT04667299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT04667299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth potassium citrate
Description: 0.6g bid
Study NCT04667299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 0.4g qid
Study NCT04667299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: 0.4g qid
Study NCT04577274 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: conventional diabetic enteral drinks (Glucerna)
Description: Participants were given 300 kcal of smoothie drink within 3-5 minutes and blood collection after drinking at 30, 60, 90, 120, 180 and 240 minutes. Participants have one week wash out period before try-out other formulas.
Study NCT04667299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1g bid
Study NCT01844284 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE PRIME®/XIENCE Xpedition™
Description: Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
Study NCT01844284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Absorb™ BVS
Description: Subjects receiving Absorb™ BVS
Study NCT04496102 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triathlon
Description: Modern TKA design (Triathlon) with patellar resurfacing
Study NCT04496102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triathlon
Description: Modern TKA design (Triathlon) with patellar resurfacing
Study NCT04259450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 mg AFM24
Description: 14 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Study NCT04259450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg AFM24
Description: 40 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Study NCT04259450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg AFM24
Description: 80 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Study NCT04259450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 mg AFM24
Description: 160 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Study NCT04259450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 320 mg AFM24
Description: 320 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Study NCT04259450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 480 mg AFM24
Description: 480 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Study NCT04259450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 720 mg AFM24
Description: 720 milligram AFM24 weekly on Day 1, Day 8, Day 15, and Day 22 of a 28-day cycle.
Study NCT04475549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-6463 Tablets
Description: IW-6463 tablets administered orally (daily)
Study NCT00673309 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stable Isotope Infusion study
Description: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Study NCT00673309 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stable Isotope Infusion study
Description: Stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues. Includes collection of blood and tissues (muscle)
Study NCT00673309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin High Dose
Description: Insulin IV administered continuously throughout hospitalization until wounds are 95% healed.
Study NCT00673309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxandrolone
Description: Oxandrolone given daily throughout hospitalization until 95% wound healing.
Study NCT00673309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol to be given daily throughout hospitalization until 95% wound healing.
Study NCT00673309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Recombinant Human Growth hormone to be administered daily until 95% wound healing.
Study NCT00673309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Low Dose
Description: Insulin administered IV until 95% wound healing
Study NCT00673309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGF-1/IGFBP-3
Description: Insulin Like Growth Factor-1/Insulin like Growth Factor Binding Protein 3 administered until 95% wound healing
Study NCT00673309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole administered until 95% wound healing
Study NCT00673309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone and Propranolol
Description: Growth Hormone and Propranolol given until 95% wound healing
Study NCT00673309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone and Propranolol
Description: Oxandrolone and Propranolol
Study NCT00673309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo or Control
Description: Administration of Placebo or Control until 95% wound healing
Study NCT03670667 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT03383770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia Touhy
Description: The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A touhy cannula is used.
Study NCT03383770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regional Anesthesia Facet
Description: The patients receive the planned anaesthesia procedure according to the procedure to be performed. Only nerve blockages are carried out, which are considered to be analgesic useful for the planned operations on the basis of typical nerve courses. A facet cannula is used.
Study NCT01332409 — intervention group
Intervention type: DRUG
Intervention: Salmeterol and Fluticasone
Description: Administered according to the prescribing information in the locally approved label by the authorities.
Study NCT00255931 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy and Relaxation/biofeedback
Study NCT00255931 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Placebo
Description: Untrained relaxation
Study NCT04166253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Alfacalcidol oral tablets once daily
Study NCT03044964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
Study NCT03044964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
Study NCT03246282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVL1000 Treatment Station
Description: Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter
Study NCT03246282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: 250 ml of 0.9% Sodium Chloride Solution
Study NCT03246282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Catheterization
Description: 20-gauge 1.0 catheter
Study NCT02362048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Study NCT02362048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196 in combination with pembrolizumab
Study NCT01484548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3 + GLA-SE
Description: 20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
Study NCT01484548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LEISH-F3 + GLA-SE
Description: 20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
Study NCT01484548 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LEISH-F3 alone
Description: 20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
Study NCT02142933 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: vagino-perineal swab
Study NCT00790010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Plus Ipilimumab Cohort 1
Description: Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
Study NCT00790010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Plus Ipilimumab Cohort 2
Description: Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
Study NCT00790010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Plus Ipilimumab Cohort 3
Description: Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
Study NCT00790010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Plus Ipilimumab Cohort 4
Description: Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
Study NCT04602312 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Meditation (1 x 20-minute guided audio training)
Description: Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.